vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and Solaris Energy Infrastructure, Inc. (SEI). Click either name above to swap in a different company.
Solaris Energy Infrastructure, Inc. is the larger business by last-quarter revenue ($196.2M vs $177.4M, roughly 1.1× Pacira BioSciences, Inc.). Solaris Energy Infrastructure, Inc. runs the higher net margin — 16.3% vs 1.6%, a 14.7% gap on every dollar of revenue. On growth, Solaris Energy Infrastructure, Inc. posted the faster year-over-year revenue change (9.2% vs 5.0%). Over the past eight quarters, Solaris Energy Infrastructure, Inc.'s revenue compounded faster (63.0% CAGR vs -0.2%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
AGL Energy Ltd is an Australian listed public company involved in both the generation and retailing of electricity and gas for residential and commercial use. It is one of the "big three" retailers in the National Electricity Market. AGL is Australia's largest electricity generator, and the nation's largest carbon emitter.
PCRX vs SEI — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $196.2M |
| Net Profit | $2.9M | $32.1M |
| Gross Margin | — | — |
| Operating Margin | 3.9% | 25.8% |
| Net Margin | 1.6% | 16.3% |
| Revenue YoY | 5.0% | 9.2% |
| Net Profit YoY | — | 1013.5% |
| EPS (diluted) | $0.07 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | $196.2M | ||
| Q4 25 | $196.9M | $179.7M | ||
| Q3 25 | $179.5M | $166.8M | ||
| Q2 25 | $181.1M | $149.3M | ||
| Q1 25 | $168.9M | $126.3M | ||
| Q4 24 | $187.3M | $96.3M | ||
| Q3 24 | $168.6M | $75.0M | ||
| Q2 24 | $178.0M | $73.9M |
| Q1 26 | $2.9M | $32.1M | ||
| Q4 25 | — | $-1.7M | ||
| Q3 25 | $5.4M | $14.6M | ||
| Q2 25 | $-4.8M | $12.0M | ||
| Q1 25 | $4.8M | $5.3M | ||
| Q4 24 | — | $6.3M | ||
| Q3 24 | $-143.5M | $-968.0K | ||
| Q2 24 | $18.9M | $6.2M |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | — | ||
| Q3 25 | 80.9% | — | ||
| Q2 25 | 77.4% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 76.9% | — | ||
| Q2 24 | 75.1% | — |
| Q1 26 | 3.9% | 25.8% | ||
| Q4 25 | 1.2% | 22.2% | ||
| Q3 25 | 3.5% | 22.7% | ||
| Q2 25 | 4.7% | 23.8% | ||
| Q1 25 | 1.2% | 17.5% | ||
| Q4 24 | 13.2% | 26.7% | ||
| Q3 24 | -82.8% | 7.0% | ||
| Q2 24 | 15.9% | 16.0% |
| Q1 26 | 1.6% | 16.3% | ||
| Q4 25 | — | -0.9% | ||
| Q3 25 | 3.0% | 8.7% | ||
| Q2 25 | -2.7% | 8.0% | ||
| Q1 25 | 2.8% | 4.2% | ||
| Q4 24 | — | 6.5% | ||
| Q3 24 | -85.1% | -1.3% | ||
| Q2 24 | 10.6% | 8.4% |
| Q1 26 | $0.07 | $0.32 | ||
| Q4 25 | $0.05 | — | ||
| Q3 25 | $0.12 | — | ||
| Q2 25 | $-0.11 | — | ||
| Q1 25 | $0.10 | — | ||
| Q4 24 | $0.38 | — | ||
| Q3 24 | $-3.11 | — | ||
| Q2 24 | $0.39 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | $344.5M |
| Total DebtLower is stronger | — | $395.4M |
| Stockholders' EquityBook value | $653.9M | — |
| Total Assets | $1.2B | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | $344.5M | ||
| Q4 25 | $238.4M | $353.3M | ||
| Q3 25 | $246.3M | $106.7M | ||
| Q2 25 | $445.9M | $99.6M | ||
| Q1 25 | $493.6M | $16.7M | ||
| Q4 24 | $484.6M | $114.3M | ||
| Q3 24 | $453.8M | $18.6M | ||
| Q2 24 | $404.2M | $5.1M |
| Q1 26 | — | $395.4M | ||
| Q4 25 | $372.2M | $184.0M | ||
| Q3 25 | $376.7M | $382.8M | ||
| Q2 25 | $580.5M | $386.2M | ||
| Q1 25 | $583.4M | $316.2M | ||
| Q4 24 | $585.3M | $315.7M | ||
| Q3 24 | — | $315.3M | ||
| Q2 24 | — | — |
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $564.3M | ||
| Q3 25 | $727.2M | $546.6M | ||
| Q2 25 | $757.8M | $399.1M | ||
| Q1 25 | $798.5M | $361.3M | ||
| Q4 24 | $778.3M | $355.6M | ||
| Q3 24 | $749.6M | $221.7M | ||
| Q2 24 | $879.3M | $204.6M |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $2.1B | ||
| Q3 25 | $1.3B | $1.6B | ||
| Q2 25 | $1.5B | $1.5B | ||
| Q1 25 | $1.6B | $1.1B | ||
| Q4 24 | $1.6B | $1.1B | ||
| Q3 24 | $1.5B | $939.5M | ||
| Q2 24 | $1.6B | $457.8M |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | 0.33× | ||
| Q3 25 | 0.52× | 0.70× | ||
| Q2 25 | 0.77× | 0.97× | ||
| Q1 25 | 0.73× | 0.88× | ||
| Q4 24 | 0.75× | 0.89× | ||
| Q3 24 | — | 1.42× | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
SEI
| Leasing revenue | $105.4M | 54% |
| Service revenue | $90.9M | 46% |
